CD177 and Alzheimer disease: These include a common variant of Transcription factor PU.1 (SPI1) for microglial development and function (Kierdorf et al., 2013; London et al., 2013), which is associated with a reduced risk of AD (Huang et al., 2017), as well as an allelic variant of the TREM2, a cell-surface receptor exclusively of microglial cells (Colonna, 2003) which is associated to increased risk for developing AD up to threefold (Jonsson et al., 2013; Abduljaleel et al., 2014; Ulrich et al., 2017).